Multicenter Study of Epidemiological Cutoff Values and Detection of Resistance in Candida spp. to Anidulafungin, Caspofungin, and Micafungin Using the Sensititre YeastOne Colorimetric Method

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 11, 2015, Pages 6725-6732

  Espinel Ingroff, A ^a   Alvarez Fernandez, M ^b   Canton E ^c   Carver, P L ^d   Chen, S C A ^e   Eschenauer, G ^d,f   Getsinger, D L ^g   Gonzalez, G M ^h   Govender, N P ⁱ   Grancini, A ^j   Hanson, K E ^k   Kidd, S E ^l   Klinker, K ^m   Kubin, C J ⁿ   Kus, J V ^o   Lockhart, S R ^p   Meletiadis, J ^q   Morris, A J ^r   Pelaez, T ^s   Quindos G ^t   Rodriguez Iglesias, M ^u   Sanchez Reus F ^v   Shoham, S ^w   Wengenack, N L ^x   Borrell Sole N ^y   Echeverria, J ^z   Esperalba, J ^aa   De La Pedrosa, E Gómez G ^ab   Garcia Garcia I ^ac   Linares, M J ^ad   Marco, F ^ae   Merino, P ^af   Peman J ^ag   Perez Del Molino L ^ah   Rosello Mayans E ^ai   Rubio Calvo, C ^aj   Ruiz Perez De Pipaon M ^ak   Yague G ^al   Garcia Effron, G ^am   Guinea, J ^s   Perlin, D S ^an   Sanguinetti, M ^ao   Shields, R ^f   Turnidge, J ^ap   more..

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^c Unidad de Microbiología del Centro de Investigación   (Spain)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^e WESTMEAD HOSPITAL   (Australia)

^f UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^g STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^h UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

ⁱ UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^j FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^k UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^l SA Pathology   (Australia)

^m UNIVERSITY OF FLORIDA   (United States)

ⁿ NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^o PUBLIC HEALTH ONTARIO   (Canada)

^p CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^q UNIVERSITY OF ATHENS   (Greece)

^r AUCKLAND CITY HOSPITAL   (New Zealand)

^s HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^t UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^u HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

^v HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^w JOHNS HOPKINS HOSPITAL   (United States)

^x MAYO CLINIC   (United States)

^y HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^z HOSPITAL DONOSTIA   (Spain)

^aa HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^ab HOSPITAL RAMÓN Y CAJAL   (Spain)

^ac HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^ad Universidad de Cordoba   (Spain)

^ae UNIVERSITY OF BARCELONA   (Spain)

^af HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^ag HOSPITAL UNIVERSITARIO LA FE   (Spain)

^ah HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^ai HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^aj HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^ak HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^al HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^am UNIVERSIDAD NACIONAL DEL LITORAL   (Argentina)

^an PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^ao CATHOLIC UNIVERSITY   (Italy)

^ap UNIVERSITY OF ADELAIDE   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANIDULAFUNGIN; CASPOFUNGIN; MICAFUNGIN; ANTIFUNGAL AGENT; ECHINOCANDIN; LIPOPEPTIDE;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; AUSTRALIA; CANADA; CANDIDA; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CLAVISPORA LUSITANIAE; COLORIMETRY; EUROPE; FUNGAL DETECTION; MEXICO; MEYEROZYMA GUILLIERMONDII; MINIMUM INHIBITORY CONCENTRATION; MUTATION; NEW ZEALAND; NONHUMAN; PICHIA KUDRIAVZEVII; PRIORITY JOURNAL; SOUTH AFRICA; UNITED STATES; DRUG EFFECTS; GENETICS; MICROBIAL SENSITIVITY TEST;

ANTIFUNGAL AGENTS; CANDIDA; ECHINOCANDINS; LIPOPEPTIDES; MICROBIAL SENSITIVITY TESTS; MUTATION;

EID: 84946209380     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01250-15     Document Type: Article

References (30)

1. Arendrup MC, Fuursted K, Gahrn-Hansen B, Schonheyder H.C., Knudsen JD, Jensen IM. 2008. Seminational surveillance of fungemia in Denmark 2004-2006: increasing incidence of fungemia and numbers of isolates with reduced azole susceptibility. Clin Microbiol Infect 14:487-494. http://dx.doi.org/10.1111/j.1469-0691.2008.01954.x.
2. Costa-de-Oliveira S, Pina-Vaz C, Mendonca D, Goncalves Rodrigues A. 2008. A first Portuguese epidemiological survey of fungaemia in a university hospital. Eur J Clin Microbiol Infect 27:365-74. http://dx.doi.org/10.1007/s10096-007-0448-4.
3. Barnes PD, Marr KA 2007. Risk, diagnosis and outcome of invasive fungal infections in haematopoietic stem cell transplant recipients. Br J Haematol 139:519-531. http://dx.doi.org/10.1111/j.1365-2141.2007.06812.x.
4. Pappas PG, Kauffman CA, Andes D, Benjamin D.K., Jr, Calandra TF, Edwards JE, Filler SG, Fischer JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48:503-535. http://dx.doi.org/10.1086/596757.
5. Cornely OA, Bassetti M, Calandra T., Garbino J, Kullberg BJ, Lortholary O, Meersseman W., Akova M, Arendrup MC, Arikan-Akdagli S, Bille J., Castagnola E, Cuenca-Estrella M, Donnelly JP, Groll A.H., Herbrecht R., Hope WW, Jensen HE, Lass-Flörl C, Petrikkos G, Richardson MD, Roilides E, Verweij PE, Viscoli C, Ullmann AJ, ESCMID Fungal Infection Study Group. 2012. ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 18:19-37. http://dx.doi.org/10.1111/1469-0691.12039.
6. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts, 3rd ed. Approved standard M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Clinical and Laboratory Standards Institute. 2012. Reference method for broth dilution antifungal susceptibility testing of yeasts Fourth informational supplement M27-S4. Clinical and Laboratory Standards Institute, Wayne, PA.
8. Shields RK, Nguyen MH, Press E.G., Clancy CJ. 2014. Abdominal candidiasis is a hidden reservoir of echinocandin resistance. Antimicrob Agents Chemother 58:7601-7605. http://dx.doi.org/10.1128/AAC.04134-14.
9. Alexander B, Johnson MD, Pfeiffer C.D., Jimenez-Ortigosa C, Catania J, Booker R., Castanheira M, Messer SA, Perlin D.S., Pfaller MA. 2013. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 56:1724-1732. http://dx.doi.org/10.1093/cid/cit136.
10. Espinel-Ingroff A., Arendrup MC, Pfaller M.A., Bonfietti LX, Bustamante B, Canton E, Chryssanthou E., Cuenca-Estrella M, Dannaoui E, Fothergill A., Fuller JF, Gaustad P, Gonzalez GM, Guarro J, Lass-Flörl C, Lockhart SR, Meis JF, Moore CB, Ostrosky-Zeichner L, Pelaez T, Pukinskas SRBS, St-Germain G, Szeszs MW, Turnidge J. 2013. Interlaboratory variability of caspofungin MICs for Candida spp. using CLSI and EUCAST methods: should the clinical laboratorybetesting this agent? Antimicrob Agents Chemother 57:5836-5842. http://dx.doi.org/10.1128/AAC.01519-13.
11. Arendrup MC, Cuenca-Estrella M, Lass-Flörl C, Hope WW, EUCAST-AFST. 2012. EUCAST technical note onthe EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). Clin Microbiol Infect 18:E246-E247. http://dx.doi.org/10.1111/j.1469-0691.2012.03880.x.
12. Arendrup MC, RodriguezTudela J-L, Park S, Garcia-Effron G, Delmas G, Cuenca-Estrella M, Gomez-Lopez A, Perlin DS. 2011. Echinocandin susceptibility testing of Candida spp. using EUCAST EDef 7.1 and CLSI M27-A3 standard procedures: analysis of the influence of bovine serum albumin supplementation, storage time, and drug lots. Antimicrob Agents Chemother 55:1580-1587. http://dx.doi.org/10.1128/AAC.01364-10.
13. Pfaller MA, Espinel-Ingroff A, Bustamante B., Canton E, Fothergill A, Fuller J., Gonzales G, Guarro J, Lass-Flörl C, Lockhart SR, Martin-Mazuelos E, Meis JF, Ostrosky-Zeichner L, Pelaez T, St-Germain G, Turnidge J. 2014. Multicenter study of anidulafungin and micafungin MIC distributions and epidemiological cutoff values for eight Candida species and the CLSI M27-A3 broth microdilution method. Antimicrob Agents Chemother 58:916. http://dx.doi.org/10.1128/AAC.02020-13.
14. Eschenauer G, Nguyen MH, Shoham S, Vazquez J.A., Morris AJ, Pasculle WA, Kubin CJ, Klinker K.P., Carver PL, Hanson KE, Chen S, Lam S.H., Potoski BA, Clarke LG, Shields RK, Clancy CJ 2014. Real-world experience with echinocandin MICs against Candida species in a multicenter study of hospitals that routinely perform susceptibility testing of bloodstream isolates. Antimicrob Agents Chemother 58:1897-1906. http://dx.doi.org/10.1128/AAC.02163-13.
15. Trek Diagnostic Systems. 2012. Sensititre YeastOne: YeastOne susceptibility, V1.8. TREK Diagnostic Systems, Cleveland, OH.
16. Espinel-Ingroff A., Chakrabarti A, Chowdhary A., Cordoba S, Dannaoui E, Dufresne P., Fothergill A, Ghannoum M, Gonzalez G.M., Guarro J., Kidd S, Lass-Flörl C, Meis JF, Pelaez T, Tortorano AM, Turnidge J. 2015. Multicenter evaluation of MIC distributions for epidemiologic cutoff value definition to detect amphotericin B, posaconazole, and itraconazole resistance among the most clinically relevant species of Mucorales. Antimicrob Agents Chemother 59:1745-1750. http://dx.doi.org/10.1128/AAC.04435-14.
17. Espinel-Ingroff A., Pfaller MA, Bustamante B, Canton E., Fothergill A, Fuller J, Gonzalez G.M., Lass-Flörl C, Lockhart SR, Martin-Mazuelos E, Meis JF, Melhem MSC, Ostrosky-Zeichner L, Pelaez T, Szeszs MW, St-Germain G, Bonfietti LX, Guarro J, Turnidge J. 2014. Multilaboratory study of epidemiological cutoff values for detection of resistance in eightCandidaspecies tofluconazole, posaconazole, and voriconazole. Antimicrob Agents Chemother 58:2006-2012. http://dx.doi.org/10.1128/AAC.02615-13.
18. Turnidge J, Kahmeter G, Kronvall G. 2006. Statistical characterization of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. Clin Microbiol Infect 12:418-425. http://dx.doi.org/10.1111/j.1469-0691.2006.01377.x.
19. Shields RK, Nguyen MH, Press E.G., Updike C., Clancy CJ. 2013. Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure. Antimicrob Agents Chemother 57:3528-3535. http://dx.doi.org/10.1128/AAC.00136-13.
20. Arendrup MC, Perlin DS 2014. Echinocandin resistance: an emerging clinical problem? Curr Opin Infect Dis 27:484-492. http://dx.doi.org/10.1097/QCO.0000000000000111.
21. Carrizosa MM. 2015. Candida parapsilosis, C. orthopsilosis and C. metapsilosis: epidemiología de las candidemias, patrones de sensibilidad y mecanismos de resistencia a las equinocandinas. Doctoral thesis. Universitat Autònoma de Barcelona, Facultat de Ciències, Departament de Genètica i Microbiologia, Barcelona, Spain.
22. Garcia-Effron G., Kontoyiannis DP, Lewis R.E., Perlin DS. 2008. Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. Antimicrob Agents Chemother 52:4181-4183. http://dx.doi.org/10.1128/AAC.00802-08.
23. Guinea J, Zaragoza Ó, Escribano P, Martín-Mazuelos E, Pemán J, Sánchez-Reus F, Cuenca-Estrella M, on behalf of the CANDIPOP Project, GEIH-GEMICOMED (SEIMC), and REIPI. 2014. Molecular identification and antifungal susceptibility of yeast isolates causing fungemia collected in a population-based study in Spain in 2010 and 2011. Antimicrob Agents Chemother 58:1529-1537. http://dx.doi.org/10.1128/AAC.02155-13.
24. Posteraro B, Spanu T, Fiori B., De Maio F, De Carolis E, Giaquinto A, Prete V., De Angelis G, Torelli R, D'Inzeo T, Vella A, De Luca A, Tumbarello M, Ricciardi W, Maurizio Sanguinetti M. 2015. Antifungal susceptibility profiles of bloodstream yeast isolates by Sensititre YeastOne over nine years at a large Italian teaching hospital. Antimicrob Agents Chemother 59:3944-3955. http://dx.doi.org/10.1128/AAC.00285-15.
25. Howell SA, Hazen KC 2011. Candida, Cryptococcus, and other yeasts of medical importance: mycology, p 1793-1821. In Versalovic J, Carroll KC, Jorgensen JH, Funke G, Landry ML, Warnock DW (ed), Manualofclinical microbiology, 10th ed, vol 2. ASM Press, Washington, DC.
26. Espinel-Ingroff A., Fothergill A, Fuller J., Johnson E, Pelaez T, Turnidge J. 2011. Wild-Type MIC distributions and epidemiological cutoff values for caspofungin and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). Antimicrob Agents Chemother 55:2855-2859. http://dx.doi.org/10.1128/AAC.01730-10.
27. Canton E, Pemán J, Hervás D, Iñiguez C, Navarro D., Echeverría J, Martínez-Alarcón J, Fontanals D, Gomila-Sard B, Buendía B, Torroba L, Ayats J, Bratos A, Sánchez-Reus F, Fernández-Natal I. FUNGEMYCA Study Group. 2012. Comparison of three statistical methods for establishing tentative wild-type population and epidemiological cutoff values for echinocandins, amphotericin B, flucytosine, and sixCandidaspecies as determinedby the colorimetric Sensititre YeastOne method. J Clin Microbiol 50:3921-3926. http://dx.doi.org/10.1128/JCM.01730-12.
28. Beyda ND, John J, Kilic A., Alam MJ, Lasco TM, Garey KW. 2014. FKS mutant Candida glabrata risk factors and outcome factors in patients with candidemia. Clin Infect Dis 59:819-825. http://dx.doi.org/10.1093/cid/ciu407.
29. Castanheira M, Woosley LN, Messer S.A., Diekema DJ, Jones RN, Pfaller MA. 2014. Frequency of fks mutations among Candida glabrata isolates from a 10-year global collection of blood stream infections isolates. Antimicrob Agents Chemother 58:577-580. http://dx.doi.org/10.1128/AAC.01674-13.
30. Pham CD, Iqbal N, Bolden C.B., Kuykendall RJ, Harrison LH, Farley MM, Schaffner W, Beldavs Z.G., Chiller TM, Park BJ, Cleveland AA, Lockhart SR 2014. Role of FKS mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance. Antimicrob Agents Chemother 58:4690-4696. http://dx.doi.org/10.1128/AAC.03255-14.